Reviewing Cocrystal Pharma Inc. (COCP)’s and bluebird bio Inc. (NASDAQ:BLUE)’s results

Both Cocrystal Pharma Inc. (NASDAQ:COCP) and bluebird bio Inc. (NASDAQ:BLUE) are Biotechnology companies, competing one another. We will contrast their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cocrystal Pharma Inc. N/A 0.00 N/A 0.04 93.68
bluebird bio Inc. 39.50M 188.91 523.83M -8.19 0.00

In table 1 we can see Cocrystal Pharma Inc. and bluebird bio Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Cocrystal Pharma Inc. 0.00% 0.4% 0.4%
bluebird bio Inc. -1,326.15% -31.5% -26.6%

Risk & Volatility

Cocrystal Pharma Inc. is 90.00% more volatile than Standard & Poor’s 500 due to its 1.9 beta. bluebird bio Inc. on the other hand, has 2.44 beta which makes it 144.00% more volatile compared to Standard & Poor’s 500.

Liquidity

Cocrystal Pharma Inc.’s Current Ratio and Quick Ratio are 4.4 and 4.4 respectively. The Current Ratio and Quick Ratio of its competitor bluebird bio Inc. are 13.1 and 13.1 respectively. bluebird bio Inc. therefore has a better chance of paying off short and long-term obligations compared to Cocrystal Pharma Inc.

Analyst Recommendations

In next table is shown Cocrystal Pharma Inc. and bluebird bio Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cocrystal Pharma Inc. 0 0 0 0.00
bluebird bio Inc. 0 2 5 2.71

Competitively the average price target of bluebird bio Inc. is $147.83, which is potential 8.35% upside.

Insider and Institutional Ownership

Cocrystal Pharma Inc. and bluebird bio Inc. has shares held by institutional investors as follows: 8.2% and 0%. About 67.48% of Cocrystal Pharma Inc.’s share are held by insiders. Competitively, insiders own roughly 0.3% of bluebird bio Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cocrystal Pharma Inc. 1.71% 118.4% 11.25% 24.04% -47.49% -40.67%
bluebird bio Inc. -16.88% -23.58% -30.98% -43.22% -39.16% -42.64%

For the past year Cocrystal Pharma Inc. has stronger performance than bluebird bio Inc.

Summary

Cocrystal Pharma Inc. beats on 7 of the 11 factors bluebird bio Inc.

Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, focuses on developing antiviral therapeutics for human diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including hepatitis C virus (HCV), influenza virus, and norovirus. The company also develops targeted in-house chemical libraries consisting of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. It has research collaboration agreement with HitGen, Ltd. and InterX, Inc. to develop small molecule drug candidates against several undisclosed targets. Cocrystal Pharma, Inc. was founded in 2007 and is headquartered in Tucker, Georgia.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.